ImageneBio, Inc. (NASDAQ:IMA) Stock Short Interest Report for October

ImageneBio, Inc. (NASDAQ:IMA) was the recipient of a significant increase in short interest during the month of October. As of October 15th, there was short interest totaling 61,349 shares, an increase of 86.7% from the September 30th total of 32,852 shares. Based on an average daily trading volume, of 14,638 shares, the days-to-cover ratio is currently 4.2 days. Currently, 0.6% of the shares of the company are short sold.

ImageneBio Stock Up 1.2%

NASDAQ:IMA opened at $4.10 on Friday. The firm’s fifty day simple moving average is $4.67 and its 200-day simple moving average is $5.64. The stock has a market cap of $46.53 million, a PE ratio of -0.90 and a beta of 0.74. ImageneBio has a fifty-two week low of $3.88 and a fifty-two week high of $8.84.

ImageneBio (NASDAQ:IMA) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($0.63) EPS for the quarter, beating the consensus estimate of ($0.90) by $0.27. Equities analysts anticipate that ImageneBio will post -3.23 earnings per share for the current year.

Institutional Investors Weigh In On ImageneBio

Hedge funds and other institutional investors have recently modified their holdings of the stock. Trails Edge Capital Partners LP purchased a new position in ImageneBio in the 2nd quarter valued at approximately $1,663,824. Blue Owl Capital Holdings LP acquired a new position in ImageneBio during the second quarter worth $5,414,000. Cable Car Capital LP acquired a new position in ImageneBio during the second quarter worth $4,611,000. BlackRock Inc. purchased a new stake in ImageneBio during the second quarter worth $797,000. Finally, Stonepine Capital Management LLC purchased a new stake in ImageneBio during the second quarter worth $539,044,000. 75.00% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

IMA has been the topic of several recent research reports. Weiss Ratings restated a “sell (e+)” rating on shares of ImageneBio in a research report on Friday, September 25th. HC Wainwright began coverage on ImageneBio in a research report on Friday, August 21st. They set a “buy” rating and a $28.00 price objective for the company. One investment analyst has rated the stock with a Buy rating and two have assigned a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Reduce” and an average price target of $28.00.

About ImageneBio

ImageneBio, Inc is a biotechnology company focused on advancing precision oncology through blood-based molecular testing and data analysis. The company develops technologies designed to help identify and monitor cancer-related genomic signals using liquid biopsy samples.

Its platform is intended to support the detection and tracking of tumor biomarkers, potentially helping clinicians assess treatment response, identify disease progression, and guide more personalized cancer-care decisions.